Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rallybio Corp.

https://rallybio.com/

Latest From Rallybio Corp.

Deal Watch: Novo Nordisk Links With Flagship To Create Cardiometabolic, Rare Disease Portfolio

The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.

Deal Watch Business Strategies

Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline

Emerging Company Profile: Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.

Emerging Company Profile Rare Diseases

Exscientia And Sanofi Will Search For 15 Novel Oncology, Immunology Drugs Under New Pact

Building on an alliance dating back to 2016, Exscientia and Sanofi will use artificial intelligence and insights gleaned from patient tissue samples to seek out 15 novel therapies.

Deals Platform Technologies

Finance Watch: Ten IPOs In One Week Bring 2021 Total To 80

Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering. 

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register